Merck, Moderna cancer vaccine clears Phase 3 milestone in melanoma - BusinessToday
• Merck and Moderna announced that their cancer vaccine, intismeran, successfully met its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS) in the Phase 3 INTerpath-001 trial. • The study focused on patients with completely resected stage IIB-IV melanoma, marking a significant milestone in testing whether Moderna's mRNA technology can be effectively applied to oncology. • This success is part of a broader strategy to treat cancer earlier in its progression, with Merck currently conducting over 30 registrational studies across various cancer types.
businesstoday.in


